In the article the authors describe a new field of study converging AI, basic research, and medicine referred to as Longevity Medicine. Another definition for Longevity Medicine is the preventative and restorative medicine enabled by the deep aging clocks and artificial intelligence. The article was authored by Alex Zhavoronkov, the founder and chief longevity officer of Deep Longevity, a computer scientist with a PhD in biophysics, Evelyne Yehudit Bischof, a practicing medical doctor trained in the top European and the US medical schools actively engaged in aging research and gerooncology at the University Hospital Basel in Switzerland, and at Shanghai University of Medicine and Health Sciences, and one of the most prolific scientists and entrepreneurs in artificial intelligence, Kai-Fu Lee. The traditional approach to medicine is to treat diseases. However, scientists estimate (Cutler and Mattson, 2006) that complete elimination of cancer would result in only 2.3 year increase in life expectancy in the US at birth and 1.3 year gain at age 65.

Artificial intelligence and deep learning. The last 10 years have seen huge advancements in machine learning, a part of artificial intelligence where …

Recent advances in deep learning enabled the development of AI systems that outperform humans in many tasks and have started to empower scientists and physicians with new tools. In this Comment, we discuss how recent applications of AI to aging research are leading to the emergence of the field of longevity medicine. Aging is a universal feature shared by all living beings. While the rate of aging may vary among individuals and species, the time elapsed since birth is a strong predictor of health status and mortality. Targeting aging may extend the average life expectancy more substantially than prevention or treatment of individual diseases1.

Deep Longevity, which specialises in the development and the application of next-generation AI for aging and longevity research, has announced the publication of an article in Nature Aging titled Artificial Intelligence in Longevity Medicine, written by Alex Zhavoronkov, Evelyne Yehudit Bischof and Kai-Fu Lee. Longevity.Technology: Longevity and AI are deeply enmeshed; from accelerating innovation and technology transfer, to developing personalised health therapies, the presence of AI is a key factor in extending lifespan and healthspan and ensuring maximum wellness. Next-generation AI could not only improve longevity investigative strategies and research, but push them in entirely new directions – vive la révolution! Hong Kong-based Deep Longevity was spun out of Insilico Medicine and quickly acquired by Regent Pacific. It develops explainable AI systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological and psychological levels, as well as developing systems for the emerging field of longevity medicine. Creators of deep aging clocks that leverage data from multiple biomarkers, Deep Longevity, through a research partnership with Human Longevity, Inc, provides various aging clocks to physicians and researchers.

In the article the authors describe a new field of study converging AI, basic research, and medicine referred to as Longevity Medicine. Another definition for Longevity Medicine is the preventative and restorative medicine enabled by the deep aging clocks and artificial intelligence. The article was authored by Alex Zhavoronkov, the founder and chief longevity officer of Deep Longevity, a computer scientist with a PhD in biophysics, Evelyne Yehudit Bischof, a practicing medical doctor trained in the top European and the US medical schools actively engaged in aging research and gerooncology at the University Hospital Basel in Switzerland, and at Shanghai University of Medicine and Health Sciences, and one of the most prolific scientists and entrepreneurs in artificial intelligence, Kai-Fu Lee. The traditional approach to medicine is to treat diseases. However, scientists estimate (Cutler and Mattson, 2006) that complete elimination of cancer would result in only 2.3 year increase in life expectancy in the US at birth and 1.3 year gain at age 65.

Aging is a universal feature shared by all living beings. While the rate of aging may vary among individuals and species, the time elapsed since birth is a strong predictor of health status and mortality. Targeting aging may extend the average life expectancy more substantially than prevention or treatment of individual diseases1. However, within the established drug discovery and development framework, pharmaceutical companies are still searching for compounds and interventions for the treatment of individual chronic diseases such as cancer and cardiovascular or pulmonary diseases. Current biomedical research aims to identify the underlying mechanisms and molecular targets specific to a disease in order to modify the disease, treat its symptoms or cure it.